BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Target Hit|| Long (1Y)
HDFC Securities Recommends ‘Neutral’ On Alembic Pharma
According to HDFC Securities, significant benefits from Alembic Pharma's recent investments are back-ended and will be realized from the second half of FY20.